IE85318B1 - (R-(R*R*))-2-(4-fluorophenyl)-á,d-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof - Google Patents
(R-(R*R*))-2-(4-fluorophenyl)-á,d-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereofInfo
- Publication number
- IE85318B1 IE85318B1 IE2004/0325A IE20040325A IE85318B1 IE 85318 B1 IE85318 B1 IE 85318B1 IE 2004/0325 A IE2004/0325 A IE 2004/0325A IE 20040325 A IE20040325 A IE 20040325A IE 85318 B1 IE85318 B1 IE 85318B1
- Authority
- IE
- Ireland
- Prior art keywords
- compound
- heptanoic acid
- hydroxide
- treating
- formula
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 22
- 239000011780 sodium chloride Substances 0.000 title claims abstract description 21
- 125000000686 lactone group Chemical group 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 19
- 238000007792 addition Methods 0.000 claims description 8
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 claims description 3
- 208000009576 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010062060 Hyperlipidaemia Diseases 0.000 claims description 2
- NCNCGGDMXMBVIA-UHFFFAOYSA-L Iron(II) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- LALRXNPLTWZJIJ-UHFFFAOYSA-N Triethylborane Chemical compound CCB(CC)CC LALRXNPLTWZJIJ-UHFFFAOYSA-N 0.000 claims description 2
- UGZADUVQMDAIAO-UHFFFAOYSA-L Zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 229960004887 ferric hydroxide Drugs 0.000 claims description 2
- MSNWSDPPULHLDL-UHFFFAOYSA-K iron(3+);trihydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- 229910021511 zinc hydroxide Inorganic materials 0.000 claims description 2
- 229940007718 zinc hydroxide Drugs 0.000 claims description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N Heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- KOTYNWBVGZFLLM-JWXFUTCRSA-N (2R,3R,4S,5S)-5-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CN[C@@](C)(O)[C@@H](O)[C@H](O)[C@H](O)CO KOTYNWBVGZFLLM-JWXFUTCRSA-N 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 241001313871 Puma Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 26
- 239000000047 product Substances 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 150000002596 lactones Chemical group 0.000 description 14
- 239000002253 acid Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000008079 hexane Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000012452 mother liquor Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- -1 4-FLUOROPHENYL Chemical class 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 159000000001 potassium salts Chemical class 0.000 description 4
- 229940107161 Cholesterol Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037348 biosynthesis Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1H-pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- OTCKOJUMXQWKQG-UHFFFAOYSA-L Magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 235000011116 calcium hydroxide Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001623 magnesium bromide Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AKWIAIDKXNKXDI-UHFFFAOYSA-N 1H-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-MIGRVSMKSA-N 3-Hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-MIGRVSMKSA-N 0.000 description 1
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-Hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 1
- FAHBNUUHRFUEAI-UHFFFAOYSA-M Aluminium hydroxide oxide Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 229940093530 Coenzyme A Drugs 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N Mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N Tert-Butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CROBTXVXNQNKKO-UHFFFAOYSA-N borohydride Chemical compound [BH4-] CROBTXVXNQNKKO-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 101710031899 moon Proteins 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Abstract
ABSTRACT [R—(R*,R*)] — 2 — (4—f1u0ropheny1) -B,6—dihydroXy—5—((1—methylethy1)—3-phenyl—4- [(pheny1amino)-carboyn1]-1H—pyrrole-l—heptanoic acid or (2R—trans)—5—(4— fluoropheny1)—2—( 1—methy1ethy1—N, 4—dipheny1—l[2-(tetrahydro—4—hydroxy—6—oxo—2H— pyran—2—y1)ethy1]-1H-pyrrole-3—carboxamide; a process for their preparation and pharmaceutically acceptable salts thereof.
Description
PATENTS ACT, 1992
2004/0325
(R-(R*R*))(4—FLUOROPHENYL)-B,5-DTHYDROXY—b—(l—
METHYLETHYLPHENYL-4((PHENYLAMTNO)-CARBONYL)-lH-
PYRROLE-l—HEPTANOIC ACID, ITS LACTONE FORM AND SALTS
THEREOF
WARNER-LAMBERT COMPANY
It is now unexpectedly found that the enantiomer having
the R form of the ring-opened acid of trans—5-(4-
fluorophenyl)(1-methylethyl)-N,4-diphenyl[2-
tetrahydrohydroxyoxo-2g-pyranyl)ethyl]
pyrrolecarboxamide; that is [R—(R*,R*)](4-
fluorophenyl)-B,5-dihydroxy(1-methylethyl)-3—phenyl
[(phenylamino)carbonyl]-lg-pyrroleheptanoic acid,
provides surprising inhibition of the biosynthesis of
cholesterol.
It is known that 3-hydroxymethylglutaryl coenzyme A
(HMG-CoA) exists as the 3R-stereoisomer. Additionally, as
shown in the study of a series of 5-substituted
3,5-dihydroxypentanoic acids by Stokker et al., in
"3-Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitors.
1. Structural Modification of 5-Substituted
3,5-Dihydroxypentanoic acids and Their Lactone Derivatives,"
J. Med. Chem. 1985, 28, 347-358, essentially all of the
biological activity resided in the trans diastereomer of
(E)[2-(2,4-dichlorophenyl)ethenyl]—3,4,5,6-tetrahydro—4—
hydroxy-2H-pyranone having a positive rotation. Further,
the absolute configuration for the B—hydroxylactone
moiety common to mevinolin of the formula (la)
O
HO 3 O
0 CH3 1 a
Of
H3C‘
and compactin of the formula (lb)
0
HO O
Of
H‘
apparently is required for inhibition of HMG-CoA reductase.
This is reported by Lynch et al. in "Synthesis of an HMG-COA
Reductase Inhibitor; A Diastereoselective Aldol Approach in
Tetrahedron Letters, Vol. 28, No. 13, pp. 1385-1388 (1987)
as the 4R, 6R configuration.
However, an ordinarily skilled artisan may not predict
the unexpected and surprising inhibition of cholesterol
biosynthesis of the present invention in view of these
disclosures.
l\)
V.) I
SUMMARY OF THE INVENTION
Accordingly the present invention provides for
compounds consisting of [R—(R*R*)]—2—(4—fluorophenyl)—B,é—
dihydroxy—5—((l—methylethyl)—3—phenyl—4~[(phenylamino)—
carbonyl]-lH—pyrrole—l—heptanoic acid (compound of formula
I), and pharmaceutically acceptable salts thereof.
suffering from hypercholesterolemia or hyperlipidemia.
DETAILED DESCRIPTION OF THE INVENTION
The pharmaceutically acceptable salts of the invention
are those generally derived by dissolving the free acid or
the lactone; preferably the lactone, in aqueous or aqueous
alcohol solvent or other suitable solvents with an
appropriate base and isolating the salt by evaporating the
solution or by reacting the free acid or lactone; preferably
the lactone and base in an organic solvent in which the salt
separates directly or can be obtained by concentration of the
solution.
In practice, use of the salt form amounts to use of the
acid or lactone form. The
able salts within the scope of the invention are those
pharmaceutically accept-
derived from bases such as sodium hydroxide, potassium
hydroxide, lithium hydroxide, calcium hydroxide, 1-deoxy
(methylamino)-D-glucitol, magnesium hydroxide, zinc
hydroxide, aluminum hydroxide, ferrous or ferric
hydroxide, ammonium hydroxide or organic amines such as
N-methylglucamine, choline, arginine.
Preferably, the lithium, calcium, magnesium, aluminum and
ferrous or ferric salts are prepared from the sodium or
potassium salt by adding the appropriate reagent to a
solution of the sodium or potassium salt, i.e., addition of
calcium chloride to a solution of the sodium or potassium
salt of the compound of the formula I will give the calcium
salt thereof.
The free acid can be prepared by hydrolysis of the
lactone form of formula II or by passing the salt through a
cationic exchange resin (H + resin) and evaporating the
water.
Generally, the compounds I and II of the present
invention can be prepared by (l) resolving the racemate,
that is prepared by the processes described in U.S. Patent
No.
or (2) synthesizing the desired chiral form beginning from
,681,893 which is incorporated by reference therefor,
starting materials which are known or readily prepared using
processes analogous to those which are known.
Specifically, resolution of the racemate may be
accomplished as shown in Scheme I (where Ph is phenyl) as
follows:
' Scheme 1
IO on on o
/\/k)\)\ 3
pm R R S ‘ "1
mm N ° ° C33
u 5 21: R
‘ 0 " ‘T’ Step A
+
(cs: ‘""
I
F
trans racqmatg
OH OH 0
H
Pb ’”‘\/’i\»/£‘\¢’l\
N 5 5 N = Ph
PhHN H
CH3
° R
Step B
) Separate
2) Na0H
V3) reflux in toluene
no 0 aqwy O
0 O
w
@xiz*©X:z*
h Ph CONHh
Ph CONE?
[R(R'R*) 1 isomer [S (R*R*) lisomer
Naofi naoa
C0733 CO7Na
moon 08
ohm OH
1' F
©X:r‘ “
yh cgngph Pb Coflflh
The "trans racemate” of Scheme 1 means a mixture of the
following:
H0 0 Ho 0
‘C? O
and F
Ph CONHPh Ph CONHph
"'1
Z
$ —\mu
[R (R*R*> J isomer [5 (R*R*) ]isomer
The conditions of the Step 1 and 2 of Scheme 1 are
generally as found in the Examples 6 and 7 hereinafter.
The chiral synthesis is shown in Scheme 2 (where Ph is
phenyl) as follows:
Scheme 2
F
.M9“
CD ‘~‘ , 1. THF—80—-90°C
0‘ Ph 2 1hr
X ' G
0 + O 0 2.Adm
F
1.1 eq NaOMe
0 Ph OH
M OH, -10 C
e l6hrs ’ N/\)\/CO2”
PhNHOC
(4)
% (3) 75%
o
"L\0Bu‘ 8 99 1. B(Et)3 , NaBH4
on 0 --~---——--------*
Ph 2 . H202
-40°C N CO2But
Shrs
PhNHOC
(5) 78%
F
on
1. NaOH
Ph OH OH 2. T01. -H20‘* Ph
,» N,»\V/J\\//L\¢,CO2But -------> N O O
“ PhNHOC H
PhNHOC
(7) 57%
Generally, conditions for Scheme 2 are as shown in the
Examples 1-5 hereinafter.
One of ordinary skill in the art would recognize
variations in the Schemes 1 and 2 which are appropriate for
the preparation of the compounds of the present invention.
The compounds according to present invention and
especially according to the compound of the formula I
inhibit the biosynthesis of cholesterol as found in the CSI
U.S. Patent No. 4,681,893 which
reference therefor. The CSI
enantiomer the compound II and
the racemate of these two compounds are as follows:
screen that is disclosed in
is now also incorporated by
data of the compound I, its
°50
Compound (micromoles/liter)
[R-(R*R*)] isomer 0.0044
[S-(R*R*)] isomer 0.44
Racemate 0.045
Accordingly, the present invention is the pharmaceu-
tical composition prepared from the compound of the
formula I or II or pharmaceutically acceptable salts
thereof.
These compositions are prepared as described in U.S.
Patent No. 4,681,893 which is, therefore, again incorporated
by reference here.
Likewise, the present invention is a method of use as
hypolipidemic or hypocholesterolemic agents.
of the
method
The compounds
present invention utilized in the pharmaceutical
of this invention are administered to the patient at
dosage levels of from 10 to 500 mg per day which for a
normal human adult of approximately 70 kg is a dosage of
from 0.14 to 7.1 mg/kg of body weight per day. The dosages
may be preferably from 0.5 to 1.0 mg/kg per day.
The dosage is preferably administered as a unit dosage
form. The unit dosage form for oral or parenteral use may
be varied or adjusted from 10 to 500 mg, preferably from 20
to 100 mg according to the particular application and the
potency of the active ingredient. The compositions can, if
desired, also contain other active therapeutic agents.
Determinations of optimum dosages for a particular situation
is within the skill of the art.
The compounds of the formula I and II and their pharma-
ceutically acceptable salts are in general equivalent for
the activity of the utility as described herein.
The following examples illustrate particular methods
for preparing compounds in accordance with this invention.
These examples are thus not to be read as limiting the scope
of the invention.
EXAMPLE 1
285 ml 2.2 M n-butyl lithium (in Hexane) is added
dropwise to 92 ml diisopropylamine in 300 ml THF at 50—60°C
in a 1000 ml 1 neck flask via dropping funnel and under
nitrogen. The well stirred yellow solution is allowed to
warm to about -20°C. Then it is cannulated into a
suspension of 99 g S(+)acetoxy-1,1,2-triphenylethanol in
500 ml absolute THF, kept in a 2L-3 neck flask at -70°C.
when addition is complete, the reaction mixture is allowed
to warm to —l0°C over a period of two hours. Meanwhile, a
suspension of 0.63 mol MgBr2 is prepared by dropping 564 ml
(0.63 mol) of bromine into a suspension of 15.3 g of
magnesium (0.63 mol) in 500 ml THF plus in 3L flask equipped
When this is
completed, the MgBr2 suspension is cooled to -78°C and the
with reflux condenser, and overhead stirrer.
enolate solution (dark brown) is cannulated into the
suspension within 30 minutes. Stirring is continued for 60
150 g 5-(4-fluorophenyl)(l-
minutes at -78°C.
carboxamide in 800 ml THF absolute was added dropwise over
minutes; then stirred for 90 minutes at -78°C, then
quenched with 200 ml ACOH at -78°C.
cool bath, 500 ml of H2
concentrated in vacuo at 40-50°C.
This is removed to a
O is added and the mixture
500 ml of 1:1
EtOAc/Heptane is added to the yellowish slurry and filtered.
The filtrate is washed extensively with 0.5 N Hcl, then
several times with H20 and finally with EtOAc/Heptane (3:1)
that was cooled with dry ice to -20°C. The light brown
crystalline product 1A is dried in vacuum oven at
40°C. The yield is 194 g.
The product 1A is recrystallized from EtOAc at -10°C to
yield 100 g to yield product 1B and then recrystallized from
acetone/pentane to yield 90 g to yield product 1C. The
mother liquor is combined from the wash of the crude
33 g of 1B
HPLC: 97.4:2.l7 of the R,S to S,S
28.5 g of 1C shows the following: HPLC:95.7:3.7.
The combined 1B and 1C is recrystallized from CHCl3 MeOH
material and recrystallized from EtOAc/Hexane.
shows the following:
isomers.
:1; providing a product 1F having a yield of 48.7 g of
white crystal.
The mother liquor of the first aqueous wash is
crystallized (EtOAc/Heptane) to yield product 1D of 21.4 g;
HPLC: 7l.56:25.52.
The mother liquor of 1B and 1C is combined and
recrystallized from CHCl3/MeOH/Heptane to yield 55.7 g white
crystals of product 1G.
D is recrystallized from CHCl3/MeOH to yield the
product lH.
All mother liquor is combined, concentrated then the
residue is dissolved in hot CHC13/MeOH 10:1; put on a silica
gel column; and eluted with EtOAc/Hexane 40:60. The
material crystallized out on the column and the silica gel
is extracted with CHCl3/MeOH and concentrated.
Recrystallization of the residue from CHCI3/Heptane 3:1
yields 33.7 g of product II.
The mother liquor of ll is recrystallized to yield
18.7 g of product 1K.
The mother liquor of 1K is crystallized to yield 6.3 g
of product lL.
ll, 1K and 1L is combined and recrystallized from
CHCl3/Heptane to yield 48 g.
The combined mother liquor of II, 1K, and 1L is
concentrated to yield 31 g of 1M.
The product 1F provides the following data.
Anal: 1F
m.p. 229—230°C
Calc. Found
C: 77.84 77.14
H: 6.02 6.45
N: 3.56 3.13
These data are consistent with the formula
F
Ph
Ph OH
OH
N Ph
\ Ph
PhNHCO
EXAMPLE 2
g (0.206 M) of the combined products 1F, 1G, 1H and
L of Example 1 are suspended in 800 ml Methanol/THF (5:3).
Cooled to 0°C and added to 11.7 g sodium methoxide. The
mixture is stirred until everything is dissolved, then put
in the freezer overnight. The reaction mixture is allowed
to warm to room temperature, quenched with 15 ml HOAC, then
concentrated in vacuo at 40°C to obtain expected product as
follows:
F
OH
Ph
9 N
PhNHC
This product is added to 500 ml H20 and extracted twice
with EtOAc (300 ml). The combined extracts are washed with
saturated NaHCO3, brine, dried over anhydrous magnesium
sulfate, filtered and the solvent evaporated. The residue
is chromatographed on silica gel in EtOAc/Heptane (1:4) as
eluent to yield 109 g colorless oil which is recrystallized
from Etzo/Heptane to yield:
.9 g first crop; white crystals
8.2 g second crop; white crystals.
The crystals provide the following data:
m.p,.125-125°c, (130
.23° (1.17 M, CH3OH)
Calc. Found
C: 72.76 72.51
H: 6.30 6.23
N: 5.30 5.06
These data are consistent with the formula
-13..
F
Pb /’ OH
N /W COZME
X
PhNHCO
EXAMPLE 3
ml of diisopropylamine is dissolved in 250 ml THF in
a 2000 ml three-neck flask equipped with thermometer and
dropping funnel. The reaction mixture is kept under
nitrogen. The mixture is cooled to —42°C and added to
200 ml 2.2 M of n-butyl lithium (in Hexane) dropwise over 20
minutes and stirred for 20 minutes before adding dropwise
62 ml of t-butylacetate, dissolved in 200 ml THF (over about
minutes). This mixture is stirred 30 minutes at -40°C,
then l40_ml 2.2 M of n-butyl lithium is added over 20
minuutes. when addition is complete, 81 g of the product of
Example 2 in 500 ml absolute THF is added as
possible without allowing the temperature to
-40°C.
reaction mixture is then quenched with 69 ml
quickly as
rise above
at -70°C. The
glacial acetic
Stirring is continued for four hours
acid and allowed to warm to room temperature. The mixture
is concentrated in vacuo and the residue is taken up in
EtOAc, washed with water extensively, then saturated NH4Cl,
NaHCO
layer is dried over anhydrous MgSO4, filtered and the
(saturated), and finally with brine. The organic
solvent evaporated. The NMR of the reaction is consistent
with starting material plus product in about equal amounts
plus some material on the baseline of the TLC. The material
of the baseline of the TLC is separated from starting
material and the product is extracted by acid/base
extraction. The organic phase is dried and concentrated in
vacuo to yield 73 g. The NMR and TLC are consistent with
the formula
F
OH O O
1/
Ph /“\./l\v/fl\o/J\
N OtBu
&
PhNHCO
EXAMPLE 4
g crude product of Example 3 is dissolved in 500 ml
absolute THF and 120 ml triethyl borane is added, followed
by 0.7 g t-butylcarboxylic acid. is stirred
to -78°C and
sodium
-78°C for six
Then poured slowly into a 4:1:l mixture of ice/30%
H202/H20.
warm to room temperature.
The mixture
under a dry atmosphere for 10 minutes, cooled
70 ml methanol is added and followed by 4.5 g
borohydride. The mixture is again stirred at
hours.
This mixture is stirred overnight then allowed to
CHC13 (400 ml) is added and the mixture is partitioned.
The water layer is extracted again with CHCI3. The organic
extracts are combined and washed extensively with H20 until
no peroxide could be found.
MgSO
The organic layer is dried over
4, filtered and the solvent is evaporated.
The residue is treated by flash chromatography on
silica gel, i.e. EtOAc/Hexane 1:3 to yield 51 g.
The product is dissolved in THF/MeOH and added to
100 ml in NaOH, then stirred for four hours at room
temperature. The solution is concentrated at room
temperature to remove organic solvent, added to 100 ml H20,
-15..
and extracted with Et2O twice. The aqueous layer is
acidified with l N HCl and extracted with EtOAc three times.
The combined organic layers are washed with H20. The
organic layer is dried with anhydrous MgSO4, filtered, and
the solvent evaporated. The residue is taken up in 2 liters
of toluene and heated to reflux using a Dean-Stark trap for
minutes.
The reaction mixture is allowed to cool to room
temperature overnight. Reflux is repeated for 10 minutes
and cooled for 24 hours.
The procedure above is repeated. The reaction is left
at room temperature for the next 10 days, then concentrated
to yield 51 g of colorless foam.
This product is dissolved in minimum CHCl and
chromatographed on silica gel eluting with EtOAc/Heptane
(50:50) to yield 23 g in pure material.
Chromatography on silica gel in CHCl3/2-propanol
(98.5:l.5) yields 13.2 g.
Calc.
C: 73.31
H: 6.15
N: 5.18
EXAMPLE 5
Preparation of 2R-trans(4-fluorophenyl)-2—(l—
methylethyl)-E,4-diphenyl[2-tetrahydro-4—hydroxy
The product of Example 4 is recrystallized from
EtOAc/Hexane. Fraction 1 yields 8.20 g of 4A. The mother
liquor yields 4.60 g of 4B! HPLC of 4B shows 100% of the
product to be the [R-(R*R*)] isomer.
to yield 4.81 g of 4C.
in CHCl3/2-propanol to yield 4.18 g colorless foam of 4D
showing ag3 + 24.53° (O.53% in CHCI3). 4C is recrystallized
A is recrystallized
4B is chromatographed on silica gel
EXAMPLE 6
Preparation of diastereomeric a-methylbenzylamides
A solution of the racemate, trans—(t)(4-
(30 g, 55.5 ml) in (R)-(+)—a-
methylbenzylamine (575 ml, 4.45 mol, 98% Aldrich) is stirred
pyrrolecarboxamide,
overnight at room temperature.
The resulting solution is then diluted with ether (2 l)
and then washed exhaustively with 2 M HCl (4 x 500 ml),
water (2 x 500 ml) and brine (2 x 500 ml).
extract is then dried over MgSO4, filtered and concentrated
The organic
in vacuo to yield 28.2 g of the diastereomeric
a-methylbenzylamides as a white solid; m.p. 174.0-177°. The
a—methylbenzylamides are separated by dissolving 1.5 g of
the mixture in 1.5 ml of 98:l.9:0.l CHCl3:CH3OH:NH4OH
(1000 mg/ml) and injecting onto a preparative HPLC column
(silica gel, 300 mm X 41.4 mm I.D.) by gastight syringe and
eluting with the above solvent mixture. Fractions are
collected by UV monitor. Diastereomer 1 elutes at
minutes. Diastereomer 2 elutes at 49 minutes. Center
cut fractions are collected. This procedure is repeated
three times and the like fractions are combined and
concentrated. Examination of each by analytical HPLC
indicates that diastereomer 1 is 99.84% pure and
diastereomer 2 is 96.53% pure. Each isomer is taken on
separately to following Examples.
To an ethanolic solution (50 M) of diastereomer 1 of
[3R-[3R*(R*),5R*]](4-fluorophenyl)—[B],[6]-
dihydroxy(l-methylethyl)phenyl[(phenylamino)
carbonyl]—N-(l-phenylethyl—lH-pyrroleheptanamide,
(l g, 1.5 mmol) is added
The resulting solution is heated
Example 6,
(hydroxy centers are both R)
1 N NaOH (3.0 ml, 3 mmol).
to reflux for 48 hours.
The solution is cooled to room temperature and
concentrated in vacuo. The residue is resuspended in water
and carefully acidified with 6 N HCl.
solution is extracted with ethyl acetate.
.46 minutes is tentatively
-carboxamide, as a white foam.
be 94.6% chemically pure [a]
peak at room temperature =
assigned to an unknown diastereomer resulting from the 2%
(S)—(-)—d—methylbenzylamine present in the Aldrich
d-methylbenzylamine.
EXAMPLE 8
Preparation of 2S-trans-5—(4-fluorophenyl)(l-
methylethyl)-3,4-diphenyl—l-[2-(tetrahydro—4—hydroxy—6-
[M1233 = 0.51% in
flash chromatographed on silica gel.
pyrrole-3—carboxamide, as a white foam.
material to be 97.83% chemically pure.
CHCI3 = -24.8%. 5
EXAMPLE 9
Hydrolysis of chemical lactone of formula II
To a room temperature, solution of the lactone in THF
The
mixture is stirred for two hours HPLC:99.65% (product); 0.34
The mixture is diluted with 3L
water, extracted with ethyl acetate (2 X 1L) and acidified
to pH X 4 by addition of 37 ml of 5N hydrochloric acid. The
aqueous layer is extracted with 2 X 1.5L portions of ethyl
is added a solution of sodium hydroxide in water.
to (starting lactone).
acetate. The combined ethyl acetate extracts are washed
with 2 X 1L of water, brine and dried, gave after filtration
the ethyl acetate solution of the required face-acid. This
solution is used directly in the fraction of the
N-methylglucamine salt.
The ethyl acetate extracts from the brine-water were
concentrated to give 15.5 g of an off-white solid.
$7.,
EXAMPLE 10
Calcium Salt from Sodium Salt and/or Lactone
Dissolve one mole lactone (540.6 g) in 5 L of MeOH;
after dissolution add 1L H20. while stirring, add one
equivalent NaOH and follow by HPLC until 2% or less lactone
and methyl ester of the diolacid remains (cannot use an
excess of NaOH, because Ca(OH)2 will form an addition of
CaCl2). Charge NaOH as caustic (51.3 ml, 98 eq.) or as
pellets (39.1 g, .98 eq.).
The above procedure is shown as follows:
O
N “"0!-i
F \ /
Ph ,0‘ .98 eq. NaOH
0 .N. —————————-
H Ph Me0H, H20
: 1
m.m= M0.6g
OH OH O
1 :1
Et0Ac, Hexane 0- +
Wash Pb ‘c‘
O .N~
Ph
Upon completion of hydrolysis, add 10 L H20, then wash
at least two times with a 1:1 mixture of EtOAc/Hexane. Each
wash should contain 10 L each of Et0Ac/Hexane. If sodium
salt is pure, add 15 L of MeOH.
contains color, add 100 g of G-60 charcoal, stir for two
Wash with 15 L Me0H.
Perform a wt/vol % on the reaction mixture, by HPLC, to
If it is impure and/or
hours and filter over supercel.
determine the exact amount of salt in solution.
Dissolve 1 eq. or slight excess CaCl2-2H20 (73.5 g) in
L H20. Heat both reaction mixture and Caclz solution to
60°C.
Add CaCl2 solution slowly, with high agitation.
After complete addition, cool slowly to 15°C and filter.
wash filter cake with 5 L H20. Dry at 50°C in vacuum oven.
Can be recrystallized by dissolving in 4 L of EtOAc
(50°C) filtering over supercel, washing with 1 L EtOAc, then
charging 3 L of hexane to the 50°C rxn solution.
The above procedure is shown as follows:
(on on o
' Ca"
m.w.- 1155.4 g 2
EXAMPLE 11
Treatment of Ethyl Acetate Solution of Free-acid of the
Formula I with N—methylglucamine
To a solution of the free-acid of the formula I
(0.106 M) in ethyl acetate (3 L) is added a solution of
N-methylglucamine (20.3 g, 0.106 m) in (1:1) water-acetone
(120 ml, 120 ml) with vigorous stirring at room temperature.
Stirring is continued for 16 hours and the hazy solution
concentrated in vacuo to ~ 250 mp. Toluene (1 L) is added
and the mixture concentrated to a white solid ~ 100 g. The
solid is dissolved in 1670 ml acetone and filtered into a
three-neck flask equipped with a mechanical stirrer and
thermostat controlled thermometer. The flask and filter is
washed with 115 ml (1:1) water-acetone and the clear
solution is cooled slowly. This provided a precipitate
which is re-dissolved by heating back to 65°C. Addition of
a further 20 ml of water followed by the washing gives a
crystalline product which was isolated by filtration. The
solids are washed with 1200 ml CH3Cl and vacuum dried at
255° to give a white solid. Analysis of this material
indicates that it contains 4% amine as well as 0.4% residual
acetone and 0.67% water. Analytical results are noted as
follows:
Melting point: 105-155°C (decomposition)
Analysis Expected: C = 63.73; H - 6.95; N = 5.57;
F2 = 9.53
Analysis Found: C = 62.10; H - 6.89; N - 5.34; F2
C = 61.92; H - 7.02; N = 5.38; F2
H20 = 0.47% (KF)
HPLC: MeOH, H20, THF (40; 550; 250)
Econosil: C18, 5u , 25 CM
256 nm: 1.0 ml/min.
6-81 min.: 98.76%
Opt. Ret.: [a]-b = -l0.33° (c = 1.00, MeOH)
Residual Solvents: CHZCH = 0.26%
Titrations: HClO4 (0.1 N) = 203.8%
Bu4NOH (0.1 N) = 98.5%
Other salts prepared in a manner analogous to those
processes appropriately selected from Examples 10 and 11
above may be the potassium salt, hemimagnesium salt,
hemizinc salt or the l—deoxy(methylamino)-D-glucitol
complex of the compound of formula I.
Claims (10)
1. [R-(R*,R*)](4-fluorophenyl)-fl,5—dihydroxy-S-(1- methylethyl)—3—phenyl[(phenylamino)carbony1]—1H-pyrrole—1— heptanoic acid and pharmaceutically acceptable salts thereof derived from bases selected form the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, 1—deoxy—2— (methylamino)—D—glucitol, magnesium hydroxide, zinc hydroxide, aluminum hydroxide, ferrous hydroxide, ferric hydroxide, ammonium hydroxide, and organic amines.
2. The monosodium salt of the heptanoic acid of claim 1.
3. The monopotassium salt of the heptanoic acid of claim 1.
4. The N-methylglucamine salt of the heptanoic acid of claim 1.
5. The hemimagnesium salt of the heptanoic acid of claim 1.
6. The hemizinc salt of the heptanoic acid of claim 1.
7. The 1-deoxy(methylamino)-D—glucitol mixture with the heptanoic acid of claim 1.
8. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
9. Use of a compound of claim 1 for the preparation of a pharmaceutical composition useful for treating hypercholesteremia or hyperlipidemia.
10. A process for the preparation of a compound according to claim 1 to 6 which comprises A)l) treating a trans racemate of the formula “<3 trans racemate with a compound of the formula to obtain compounds of the formula I on OH 0 Ph N N H Ph R R = puma HY CH3 0 R + F OH OH 0 I Ph ’“\./i\./i\v/1\ N 3 5 N = Ph PhHN H CH3 0 2) treating the compounds with a strong base; 3) refluxing the product of step 2 and 4) treating separated product of step 3 to obtain [R—(R*,R*)]— 2-(4—f1uorophenyl)—B,5-dihydroxy—5—(l—methylethyl)phenyl—4— 5 [(phenylamino)carbonyl]—1H~pyrrole—l—heptanoic acid and pharmaceutically acceptable salts thereof or B)1l treating a compound of the formula (1) F Ph 0 ” ’“\o/1\ N H R Phuag O \‘M92+ 10 ' O o‘\‘ Pb,’ /\ f0 G 0 Ph Ph (2) in tetrahydrofuran for about an hour at from about -80 to —90°C and then treated with acetic acid to obtain the compound (3) F Ph /\}\/Hy,/'\K°“ PIINHOC 2) treating the compound (3) of the step 1 with a slight excess of sodium methoxide in methanol at about —10°C for up to 16 hours to obtain the compound of the formula (4) F Pb OH Z N/\/K/CO;Me \ PhNHOC M) 3) treating the compound of 4 of step 2 with a large excess of O- 4¢L\OBut at from about -30 to -40°C for up to 5 hours to obtain the compound of formula (5) Phfiflx (5) and 4) treating the compound 5 of step 3 with triethyl borane followed by sodium borohydride in methanol followed by the addition of hydrogen peroxide to obtain [R—(R*,R*)](4- fluorophenyl)—fi,6-dihydroxy—S—(1-methylethyl)phenyl—4— [(phenylamino)carbonyl]—lH—pyrrole—1—heptanoic acid as well as the pharmaceutically acceptable salts thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USUNITEDSTATESOFAMERICA21/07/19893 | |||
US38418789A | 1989-07-21 | 1989-07-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE20040325A1 IE20040325A1 (en) | 2004-06-30 |
IE85318B1 true IE85318B1 (en) | 2009-09-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1061073B1 (en) | (R-(R*R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | |
IE83835B1 (en) | (R-(R*R*))-2-(4-fluorophenyl)-BETA,DELTA-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | |
EP0235164B1 (en) | Imidazole analogs of mevalonolactone and derivatives thereof | |
KR900001212B1 (en) | Mevalonolactones and their derivatives and process and pharmaceutical use, thereof | |
CZ285554B6 (en) | Process for preparing trans-6-[2-(substituted pyrrol-1-yl)alkyl]-pyran-2-one | |
CZ282642B6 (en) | Substituted pyridyl-dihydroxy-heptenic acid, process of its preparation, pharmaceutical composition containing thereof and intermediate for preparing the compound | |
CA2436122A1 (en) | A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds | |
PH26330A (en) | 7-(substituted-pyrrolyl)-3,5-di-hydroxyheptanoic acids | |
CZ61493A3 (en) | Synthesis process of (4r-cis)-1,1-dimethylethyl-6-cyanomethyl -2,2-dimethyl-1,3-dioxan-4-acetate | |
JP2005500351A (en) | Atorvastatin calcium in crystalline form VI and VII | |
NO327091B1 (en) | Process for preparing an enantiomerically pure form or a racemic form of HMG-COA reductase inhibitors | |
US5332857A (en) | 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents | |
RU2214409C2 (en) | N-phenylamide and n-pyridylamide derivatives, method for their preparing and pharmaceutical compositions containing thereof | |
JPH0366676A (en) | Derivative of 3,5-dihydroxy pentane acid, its preparation and anti-hypercholesterolemic agent containing same | |
IE85318B1 (en) | (R-(R*R*))-2-(4-fluorophenyl)-á,d-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | |
US5095126A (en) | Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids | |
AU2005221733A1 (en) | An improved preparation of Atorvastatin | |
EP0420266A2 (en) | Chromene or thiochromene derivatives, process for preparing the same, intermediate therefor, pharmaceutical compositions containing said derivatives and the use of said derivatives | |
NO176096B (en) | Process for preparing a pyrrole-heptanoic acid derivative | |
HU182338B (en) | Process for producing bis-hydroxybenzyl derivatives and pharmaceutical compositions containing them | |
WO1997042194A1 (en) | Process for the preparation of an indacene compound | |
JPH0115510B2 (en) | ||
EP1817027A2 (en) | Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof | |
JPS60197662A (en) | Carbamate and its preparation |